PPB - Services

Complaints, Feedback and Enquiry

Updated recommendations concerning the interaction of Ceftriaxone and Calcium containing products

[featured_image]
  • Version
  • Download 38
  • File Size 302.24 KB
  • File Count 1
  • Create Date February 15, 2022
  • Last Updated February 15, 2022

Updated recommendations concerning the interaction of Ceftriaxone and Calcium containing products

USA: The United States Food and Drugs Authority (US FDA) has notified health-care professionals of an update to an earlier alert (September 2007) that addresses the interaction of Ceftriaxone (a broad- spectrum cephalosporin antibiotic marketed as Rocephin® and generics) with calcium-containing products, based on previously reported fatal cases in neonates. The manufacturer of ceftriaxone conducted two in vitro studies using neonatal and adult plasma to assess the potential for precipitation of ceftriaxone-calcium when ceftriaxone and calcium-containing products are mixed in vials and in infusion lines.

Attached Files

FileAction
2nd message- Ca and Ceftriaxone.pdfDownload

Author

ppb_admin

Leave a comment

Your email address will not be published.